How common NF1 is in Egypt and how it progresses and is treated
Official title: Prevalence, Clinical Characteristics, Progression, and Management of Neurofibromatosis Type 1 in Egypt (NF1-Egy)
Run by AstraZeneca · NCT07221331 · Data updated 2026-11-12
This project will look at people in Egypt with neurofibromatosis type 1 to see how common it is, what symptoms they have, how it changes over time, and how it is managed.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 200 (estimated) |
| Sponsor | AstraZeneca Industry-sponsored |
| Locations | 9 sites (Al Mansurah and 8 other locations) |
| Status | Recruiting |
| Started | November 19, 2025 |
| Main results expected | September 30, 2026 |
| Study ends | September 30, 2026 |
| Registry record updated | September 11, 2026 |
| Trial ID | NCT07221331 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
People of any age diagnosed with NF1 according to NIH or revised criteria between January 1, 2010 and December 31, 2023 with available medical records are eligible.
✕Probably not a fit
People without a documented NF1 diagnosis or lacking the necessary medical records are not likely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational, multi-site project collects clinical records from patients diagnosed with NF1 in Egypt between January 1, 2010 and December 31, 2023 to describe prevalence, clinical features, disease progression, and management patterns. Inclusion requires a documented NF1 diagnosis meeting NIH or revised criteria; patients with missing diagnostic data will be excluded. Data will be drawn from participating research sites in Al Mansurah, Alexandria, and Aswān and will include information on cutaneous and plexiform neurofibromas, ocular findings, osseous lesions, and any neoplastic complications. The analysis will summarize demographic patterns, phenotype variability by age, and common treatment or monitoring approaches used in these centers.
Why it matters
Potential benefit: If successful, the findings could improve recognition, monitoring, and local care strategies for people with NF1 in Egypt.
How similar studies have gone: Similar registry and observational approaches in other countries have clarified NF1 prevalence and natural history, but large-scale, country-specific data from Egypt are limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: A. Male or female patients of any age at index date (first diagnosis of NF1 and/or PN). B. Have been diagnosed with NF1 according to the NIH Consensus Development Conference diagnostic criteria or the revised criteria between 01-Jan- 2010 and 31-December-2023. Exclusion Criteria: A. Missing NF1 diagnosis data in their medical record.
Where it's running
-
Research Site
Al Mansurah, Egypt Recruiting -
Research Site
Alexandria, Egypt Recruiting -
Research Site
Aswān, Egypt Recruiting -
Research Site
Cairo, Egypt Recruiting -
Research Site
Tanta, Egypt Recruiting -
Research Site
Asyut, Egypt Not yet recruiting
Show 3 more locations
-
Research Site
Cairo, Egypt Not yet recruiting -
Research Site
Sohag, Egypt Not yet recruiting -
Research Site
Zagazig, Egypt Not yet recruiting
Study contacts
- Study coordinator: AstraZeneca Clinical Study Information Center
- Email: information.center@astrazeneca.com
- Phone: 1-877-240-9479
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Assessing appearance concerns in Neurofibromatosis Type 1 patients
This study is trying to understand how appearance-related concerns affect people with Neurofibromatosis Type 1 by gathering their thoughts and experiences through questionnaires and discussions.
-
Evaluating HLX-1502 for Neurofibromatosis Type 1
This study is testing a new treatment called HLX-1502 to see if it can help adults with Neurofibromatosis Type 1 who have growing or painful tumors.
-
Pupillometry to measure pain and sensory problems in people with NF1
This study will test whether the AlgometRx Nociometer, a pupillometry device, can measure pain and other sensory problems in children and adults with NF1.
-
Assessing the burden of rare skin diseases
This study is trying to understand how nine rare skin diseases affect the daily lives of patients and their families, including their emotional, social, and financial challenges.
-
Using advanced MRI and AI to find early signs of cancer in children with Neurofibromatosis Type 1
This study is trying to see if advanced MRI scans and artificial intelligence can help find early signs of cancer in children with Neurofibromatosis Type 1.
-
Investigating genetic factors in childhood cancer
This study is trying to find out if certain genes passed down in families can increase the risk of childhood cancer by looking at samples from kids who have had cancer and their relatives.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.